Alkem Laboratories has launched DSS, the original De Simone formulation probiotic blend in India for restoring gut microbiota balance and managing various gut-related health conditions. The De Simone formulation is recognised as one of the world’s most extensively researched probiotics, backed by over 80 clinical trials and 200 publications over the last two decades. It is also endorsed by leading American and European gastroenterology associations in their guidelines for managing gastrointestinal disorders. Alkem has in-licensed these formulations from Next Gen Pharma India.
Alkem’s DSS range will be available in four strengths - 225 billion CFU sachet, 112.5 billion CFU capsule, 45 billion CFU capsule, and 10 billion CFU capsule - providing healthcare professionals and patients with tailored options to manage a wide spectrum of gastrointestinal conditions. Alkem is the first company offering all four strengths of this probiotic in India and also the first to launch 225 billion CFU and 10 billion CFU strengths in India, for which it has exclusive marketing rights.
The DSS probiotic contains eight live, freeze-dried bacterial strains - four Lactobacillus, three Bifidobacterium and one Streptococcus – that work to help restore gut microbiota balance and deliver proven clinical benefits.
Alkem Laboratories is among India’s leading global pharmaceutical companies. The company develops, manufactures and markets high-quality pharmaceutical products across all major therapeutic segments.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: